OTCPK:HTDS

Stock Analysis Report

Executive Summary

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Hard to Treat Diseases's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9900.0%

HTDS

6.2%

US Healthcare

0.5%

US Market


1 Year Return

n/a

HTDS

-5.7%

US Healthcare

6.8%

US Market

Return vs Industry: Insufficient data to determine how HTDS performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how HTDS performed against the US Market.


Shareholder returns

HTDSIndustryMarket
7 Day9900.0%6.2%0.5%
30 Day9900.0%2.4%-0.8%
90 Day9900.0%-1.2%-0.9%
1 Yearn/a-4.2%-5.7%9.2%6.8%
3 Year9900.0%9900.0%34.3%29.0%45.6%36.2%
5 Yearn/a65.1%55.2%63.2%45.4%

Price Volatility Vs. Market

How volatile is Hard to Treat Diseases's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hard to Treat Diseases undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Hard to Treat Diseases is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Hard to Treat Diseases has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HTDS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Hard to Treat Diseases regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Hard to Treat Diseases forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hard to Treat Diseases has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of HTDS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Hard to Treat Diseases's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Hard to Treat Diseases performed over the past 5 years?

13.9%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Hard to Treat Diseases has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Hard to Treat Diseases's financial position?


In this section we usually analyse Hard to Treat Diseases's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Hard to Treat Diseases has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of HTDS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Hard to Treat Diseases's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Hard to Treat Diseases's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate HTDS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HTDS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if HTDS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HTDS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HTDS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Hard to Treat Diseases's salary, the management and board of directors tenure and is there insider trading?


CEO

Terry Yuan 0

0yrs

Tenure

0

Shimin Yuan, Terry serves as Chief Executive Officer of Hard to Treat Diseases Inc. Shimin Yuan has been President of Shenzhen Mellow Hope Pharm since October 2001. 


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Terry Yuan

    Chief Executive Officer

    • Tenure: 0yrs
  • Sanja Pekovic

    Chief Strategy Officer and Chief Project Scientist

    • Tenure: 0yrs
  • Ivana Gadjanski

    Communication Director

    • Tenure: 0yrs
  • Carol Roberts

    Secretary

    • Tenure: 0yrs

Board Members

    Company Information

    Hard to Treat Diseases Inc.'s company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Hard to Treat Diseases Inc.
    • Ticker: HTDS
    • Exchange: OTCPK
    • Founded: 2009
    • Industry: Health Care Distributors
    • Sector: Healthcare
    • Market Cap: US$581.933k
    • Shares outstanding: 5.82b
    • Website: https://www.mellowhope.com

    Location

    • Hard to Treat Diseases Inc.
    • Room EF, 12F
    • Jinrun Mansion
    • Shenzhen
    • Guangdong Province
    • 518040
    • China

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    HTDSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2009

    Biography

    Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae ...


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2019/10/20 23:38
    End of Day Share Price2019/10/16 00:00
    Earnings2010/09/30
    Annual Earnings2009/12/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.